UPDATE: Barclays Downgrades United Therapeutics Corp. (UTHR) to Underweight
Get Alerts UTHR Hot Sheet
Price: $237.00 +1.08%
Rating Summary:
16 Buy, 9 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
16 Buy, 9 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
(Updated - November 29, 2016 8:19 AM EST)
Barclays downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Equalweight to Underweight with a price target of $100.00 (from $115.00). Analyst Geoff Meacham said Orenitram uptake will likely be hindered due to Uptravi.
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $132.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific (BSX) PT Raised to $83 at Stifel
- Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
- SL Green Realty (SLG) PT Lowered to $45 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!